1. Home
  2. VINP vs OMER Comparison

VINP vs OMER Comparison

Compare VINP & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vinci Partners Investments Ltd.

VINP

Vinci Partners Investments Ltd.

HOLD

Current Price

$9.51

Market Cap

638.8M

Sector

Finance

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$18.95

Market Cap

844.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VINP
OMER
Founded
2009
1994
Country
Brazil
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
638.8M
844.6M
IPO Year
2020
2008

Fundamental Metrics

Financial Performance
Metric
VINP
OMER
Price
$9.51
$18.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$14.00
$32.50
AVG Volume (30 Days)
40.2K
2.2M
Earning Date
05-11-2026
05-14-2026
Dividend Yield
5.72%
N/A
EPS Growth
N/A
98.15
EPS
N/A
0.77
Revenue
N/A
$29,868,000.00
Revenue This Year
$18.07
N/A
Revenue Next Year
$12.74
$233.22
P/E Ratio
$24.41
$24.61
Revenue Growth
N/A
N/A
52 Week Low
$9.19
$3.94
52 Week High
$13.61
$19.65

Technical Indicators

Market Signals
Indicator
VINP
OMER
Relative Strength Index (RSI) 54.38 71.42
Support Level $9.76 $18.00
Resistance Level $10.26 $19.65
Average True Range (ATR) 0.27 0.88
MACD 0.05 -0.14
Stochastic Oscillator 77.16 74.55

Price Performance

Historical Comparison
VINP
OMER

About VINP Vinci Partners Investments Ltd.

Vinci Compass Investments Ltd is an alternative investment platform in Brazil offering asset management, wealth management, and financial advisory services. The company comprises of six business lines i) Global IP&S, (ii) Credit (including public & private credit, opportunistic capital solutions, and agribusiness credit), (iii) Private Equity, (iv) Equities, (v) Real Assets (including real estate, infrastructure and forestry) and (vi) Corporate Advisory.

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Share on Social Networks: